A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

This study is testing a combination of an immunotherapy drug (camrelizumab, an anti-PD1 antibody) with two chemotherapy drugs (albumin-bound paclitaxel and gemcitabine) as a first-line treatment for patients with metastatic pancreatic cancer. Researchers want to find out whether adding immunotherapy to standard chemotherapy improves outcomes. **You may be eligible if you:** - Are 18 years of age or older - Have confirmed metastatic pancreatic adenocarcinoma (pancreatic cancer that has spread) - Have not received any prior systemic (whole-body) cancer treatment - Have measurable disease on scans - Are in good health (ECOG 0–1) - Have an expected survival of at least 12 weeks - Have adequate organ function (blood, liver, kidneys) **You may NOT be eligible if you:** - Have previously been treated with chemotherapy or other systemic therapy for this cancer - Have poor organ function that would make the treatment unsafe - Are unable to tolerate the study drugs Talk to your doctor to see if this trial is right for you.